Random setup errors can lead to erroneous prediction of the dose distribution calculated for a patient using a static computed tomography ͑CT͒ model. Multiple recomputations of the dose distribution covering the range of expected patient positions provides a way to estimate a course of treatment. However, due to the statistical nature of the setup uncertainties, many courses of treatment must be simulated to calculate a distribution of average dose values delivered to a patient. Thus, direct simulation methods can be time consuming and may be impractical for routine clinical treatment planning applications. Methods have been proposed to efficiently calculate the distribution of average dose values via a convolution of the dose distribution ͑calculated on a static CT model͒ with a probability distribution function ͑generally Gaussian͒ that describes the nature of the uncertainty. In this paper, we extend the convolution-based calculation to calculate the standard deviation of potential outcomes D (x,y,z) about the distribution of average dose values, and we characterize the statistical significance of this quantity using the central limit theorem. For an example treatment plan based on a treatment protocol in use at our institution, we found that there is a 68% probability that the actual dose delivered to any point (x,y,z) will be within 3% of the average dose value at that point. The standard deviation also yields confidence limits on the dose distribution, and these may be used to evaluate treatment plan stability. © 1999 American Association of Physicists in Medicine. ͓S0094-2405͑99͒02411-6͔
I. INTRODUCTION
Uncertainties arising from daily setup errors and organ motion can lead to differences between the dose distribution on a treatment plan and the actual dose distribution delivered to a patient. Two primary approaches exist to account for these uncertainties. The traditional approach measures or estimates the extent of setup uncertainty and organ motion and adds margins around a clinical target volume ͑CTV͒ to form a planning target volume ͑PTV͒. The dose is calculated on a static patient model and prescribed to the PTV, with the intent that the actual dose delivered to the CTV will be equivalent to the predicted dose distribution. This margin expansion approach does not account for the differences between the predicted dose distribution and the actual delivered dose distribution for normal tissues near the CTV. The second approach includes margins for errors and incorporates the uncertainties directly into the dose calculations, thereby giving a more complete and accurate prediction of the delivered dose distribution to both the target volume and normal tissues.
Methods based on a convolution of the static dose distribution with a function ͑generally Gaussian͒ representing the distribution of random uncertainties from setup and organ motion have been proposed for sites in the pelvis. [1] [2] [3] [4] [5] In a previous paper, we described a convolution-based method to incorporate uncertainties from intratreatment organ motion due to breathing into 3-D dose calculations. 6 In the present work, we generalize this method to incorporate uncertainties due to daily setup errors into 3-D dose calculations for radiotherapy. In doing this, we quantitatively describe potential differences between convolution-based predictions of the dose distribution and the actual dose delivered in a finitefractioned course of treatment. We confirm the validity of our approach via comparisons to direct simulations for treatment of tumors in the liver. Also, we retrospectively analyze the effects of these uncertainties on the treatment plan and dose prescriptions based on a treatment protocol for liver disease used at the University of Michigan. [7] [8] [9] 
II. METHODS AND MATERIALS
The basic algorithm for convolving setup uncertainties with a static dose distribution has been described previously. [1] [2] [3] [4] [5] The convolution method assumes rigid body motion, no change in the patient external contour, and no organ deformation. In the present study, we consider random translational setup uncertainties along the anterior-posterior ͑AP͒, left-right ͑LR͒, and superior-inferior ͑SI͒ axes.
Based on a retrospective analysis of our patient setup by Schewe et al., 10 we assume that the translations along these primary axes are independent and that the nature of the random translational setup uncertainties can be characterized by Gaussian probability distribution functions, as shown in Fig. 1 for treatment to sites in the abdomen. In this figure, the origin of coordinates corresponds to the nominal position of the patient assuming no systematic error ͑i.e., the static patient position at treatment planning͒. The mean setup uncertainty is assumed to be zero for all three axes, and we used the standard deviations in translation from Schewe's study ( LR ϭ7.4 mm, AP ϭ4.9 mm, SI ϭ5.3 mm͒.
The distribution of average dose values D (x,y,z), including random translational setup uncertainties calculated using a convolution-based method, is computed using Eq. ͑1͒:
where D (x,y,z) is the mean dose to any point x,y,z including uncertainties; D 0 (xЈ,yЈ,zЈ) is the static dose to a point xЈ, yЈ,zЈ; N is the normalized probability distribution function describing setup uncertainties in 3-D along the LR, AP, and SI axes, respectively; NϭN x (xЈϪx)N y (yЈϪy)N z (zЈϪz); and N x (xЈϪx)ϭe
, is the normal distribution with standard deviation x about a point x, similar for y and z. In theory, the integration is carried out over all space ͑Ϯϱ͒, but for a practical implementation, we cut off the integration at Ϯ3 in each direction and renormalize. As noted by Leong 1 and Killoran, 11 the distribution of average dose values calculated using Eq. ͑1͒ represents the dose distribution received by the patient given an infinite number of small fractions. However, a real course of treatment is delivered with a finite number of fractions.
Leong proposed characterizing the potential difference between a real finite fractioned treatment and the distribution of average dose values D by the standard deviation D of the average dose distribution. Killoran proposed using a Monte Carlo-based direct simulation method to account for the finite nature of treatment delivery ͑a course of treatment is simulated multiple times, allowing for the computation of the mean dose distribution as well as a range of possible outcomes about the mean dose distribution͒. However, direct simulations can be time consuming and often impractical for regular treatment planning applications.
Hence, we extended the convolution-based method to allow for an efficient computation of the standard deviation D of the average expected dose distribution D . Our method for calculating D and the statistical significance of this quantity is given below.
The general expression for the standard deviation 12 is
can be expanded and expressed as
gives the standard deviation that would result from an entire treatment delivered in a single fraction with a setup uncertainty characterized by N(xЈϪx,yЈϪy,zЈϪz). Real treatments are delivered over M multiple fractions, and so the standard deviation for a fractionated plan is smaller than D by 1/ͱM . For a fractionated plan, the probability that the absolute difference between a real treatment consisting of M fractions D M and D (x,y,z) at any point x,y,z will be less than D (x,y,z)/ͱM can be expressed using the central limit theorem 13 as The integral on the right-hand side of Eq. ͑4͒ Ϸ0.68 for k ϭ1, 0.95 for kϭ2, and 0.98 for kϭ3. We performed Monte Carlo-based direct simulations 11, [14] [15] [16] using the treatment planning system at the University of Michigan ͑UMPLAN, University of Michigan, Ann Arbor, MI͒ to confirm the validity of our convolutionbased approach to calculate D (x,y,z) and D (x,y,z). Our procedure is described below.
͑1͒ Randomly sample the setup orientation for each fraction in 3-D from the normal distributions shown in Fig. 1 . ͑The distribution was sampled over Ϯ3 and properly renormalized.͒ ͑2͒ Recalculate the dose distribution for each fraction in the new geometry using the beam weights ͑monitor units͒ from the original configuration ͑i.e., for a slightly misaligned patient, treatment would proceed under original plan assumptions, but with slightly altered patient geometry͒. ͑3͒ Combine the dose distribution from each fraction on a common grid to form one possible realization of the course of treatment. ͑4͒ Repeat procedure to calculate many possible realizations of outcome. ͑5͒ Average all realizations to determine distribution of average dose values. ͑6͒ Calculate the distribution of standard deviation values about the average dose values ͑direct simulation includes effects of fractionation in the calculation of standard deviation͒. ͑7͒ Compare the dose distribution and standard deviation distribution to the outcome of the convolution calculations.
The treatment planning geometry used for our simulations is shown in Fig. 2 . In this problem, the gross tumor volume ͑GTV͒ is located in the anterior-inferior portion of the liver. We expanded the PTV from the CTV by an amount equal to the standard deviation of the setup uncertainties in the LR, AP, and SI directions ͑i.e., LR expansion of 7.4 mm ϭ LR , AP expansion of 4.9 mm ϭ AP , SI expansion of 5.3 mm ϭ SI ). Organ motion due to breathing was not considered for this study. We treated the PTV using a right lateral beam ͑RL͒, a posterior-anterior beam ͑PA͒, and a wedged pair of oblique beams ͑RAIO, LASO͒. The 95% isodose surface completely covered the PTV ͑normalized to 100% at isocenter͒. Based on the dose to the normal liver ͑characterized by the effective volume V eff , 17 the fractional volume of an organ that if uniformly irradiated would result in the same complication probability as the nonuniform irradiated scenario͒, treatment delivery was planned for 58 fractions at 1.5 gray/fraction delivered twice daily.
We compared the distribution of average dose values calculated using Eq. ͑1͒ to the static ͑initial treatment plan͒ dose distribution. Also, we calculated dose volume histograms ͑DVHs͒ and the effective volume V eff for the convolved and static treatment plans to determine the gross effects of the setup uncertainties on the treatment plan, as per a liver dose escalation protocol.
7-9 Next, we calculated the standard deviation of the convolved dose distribution ͓D (x,y,z)͔ using Eq. ͑3͒ and evaluated the result using Eq. ͑4͒ to determine the range of potential outcomes in dose about the average dose values.
The results of our convolution-based calculations were also compared to the direct simulations, in the manner described above. We calculated upper and lower bounds on the dose distribution via calculation of D ϩ2 D /ͱM and D Ϫ2 D /ͱM , respectively ͑95% confidence limits͒. We then developed an interpretation of these bounds for the dose distribution and potential applications in the reevaluation of treatment plans using DVHs and V eff calculations. Figure 3͑a͒ shows the RL and PA beam orientation on a single axial CT slice. Figure 3͑b͒ shows a dose difference display, in which the original planning ͑static͒ dose distribution is subtracted from the distribution of average dose values (D ϪD 0 ). Dose to the CTV predicted using a static model is approximately the same as the distribution of average dose values that includes uncertainties, indicating that the margins for the PTV are sufficient. Differences up to Ϯ8% of the isocenter dose are observed in regions outside the CTV, resulting in a decrease in V eff for the normal liver sufficient to consider a change in the prescription dose assigned for this treatment plan to maintain a fixed level of toxicity. 9, 18 As discussed above, for comparison to the convolutionbased calculations, we performed multiple direct simulations for the treatment plan shown in Fig. 2 ͑58 fractions per course of treatment at 1.5 gray/fraction͒. Ten courses of treatment were computed, then averaged and compared to the distribution of average dose values D calculated using the convolution method of Eq. ͑1͒. A dose difference display ͑not shown͒ demonstrated negligible differences ͑Ͻ0.5%͒ in the regions of interest ͑normal liver, target volumes͒, with differences observed near the surface of the patient due to artifacts in the convolution calculation arising from discontinuities of the dose distribution at the patient surface. The DVHs for the target and organs at risk were indistinguishable between the average of the direct simulation calculations and the convolution-based calculation, with V eff calculations differing by less than 0.2%.
III. RESULTS
On average, the dose distribution calculated via multiple direct simulations and convolution-based methods ͓Eq. ͑1͔͒ agree ͑Ͻ0.5% differences͒, but the dose distribution from any single simulation of a course of treatment D N could deviate from that average ͓Eq. ͑1͔͒. This is shown in Fig. 4 on a single CT slice for the treatment planning geometry in Fig.  2 . For this treatment plan, we observed potential differences between direct simulations ͑58 fractions͒ and D up to 2% in regions outside the CTV.
Results from calculations of D (x,y,z)/ͱM for M ϭ58 fractions are shown in Fig. 5 for axial, coronal, and oblique CT reconstructions ͑in a plane containing beams oblique beams 3 and 4͒. The spatial distribution of D /ͱM computed via Eq. ͑3͒ agrees with calculations made via direct simulations ͑not shown, Ͻ0.2% differences͒.
IV. DISCUSSION
For the example shown, the PTV margins about the CTV were sufficiently large that a realistic dose calculation including random setup uncertainties demonstrated that the static dose calculation correctly predicted the dose to the CTV. However, random setup uncertainties during fractionated radiotherapy led to erroneous predictions of the doses to normal tissues. As seen in Fig. 3 , the maximum differences between the preplanned and average dose calculation including predicted daily variations are in normal tissue regions corresponding to the beam edges. This result agrees with clinical observations made by Michalski et al. 19 Though the example shown is specific to a particular treatment planning geometry, it is clear that including the effects of random setup uncertainties in the dose calculations can lead to changes in the prescription dose for protocols based on the predicted dose distribution to normal tissues.
The distribution of average dose values D (x,y,z) can be calculated via direct simulations of the treatment, or when appropriate, via a convolution-based calculation applied to the static dose distribution ͓Eq. ͑1͔͒. In both cases, D (x,y,z) represents the dose to points x,y,z that would be delivered to an average patient given a very large ͑infinite͒ number of fractions. The dose delivered in a finite-fractioned treatment can differ from D for even a relatively large number of fractions.
We have proposed a method to calculate the range of potential outcomes in a real treatment about D (x,y,z) using a convolution-based calculation. Using the central limit theorem, this distribution of possible outcomes can be characterized by D (x,y,z)/ͱM ͓where the standard deviation D (x,y,z) is defined in Eq. ͑3͒, and M is the number of fractions in a course of treatment͔. Calculation of D (x,y,z) Ϯ2 D (x,y,z)/ͱM can provide population-based confidence limits on our dose distribution ͑in particular for dose to sensitive structures͒ and should be considered when assigning the prescription dose.
While the upper and lower bounds on the dose distribution represent true 95% confidence limits ͑based on the central limit theorem͒, the upper bound assumes that all points in the distribution receive a dose greater than the average dose, while the lower bound assumes that all points receive a dose smaller than the average dose. These bounds may not be physically realizable because of conservation of energy ͑delivered dose͒ ͑i.e., if some points in the dose distribution receive a higher than average dose, then other points will receive a lower than average dose͒. Thus, the upper and lower bounds are true on a voxel-by-voxel basis but do not generally represent the physical ͑realizable͒ upper and lower bounds on the total dose distribution. Hence, the spatial distribution of D (x,y,z)/ͱM should be considered when evaluating the upper and lower bounds on the average dose distribution D (x,y,z).
As the number of fractions in the treatment plan increases, the range of potential outcomes about the average outcome will decrease. This is shown in Fig. 6 , where the distribution of D (x,y,z)/ͱM is compared for M ϭ10, 20, and 40 fractions using the planning geometry described in Fig. 2 . This is also seen in Fig. 7 , which shows cumulative DVHs of the normal liver based on calculations of D and D Ϯ2 D /ͱM for 10 and 40 fractions. Clearly, as the number of fractions increases, D become a better prediction of the actual dose delivered to the patient.
As noted earlier, the convolution calculation does not agree with direct simulations near the patient surface. In general, a convolution-based approach is not valid in regions where the dose distribution itself is not invariant under small changes, for example, near interfaces with large homogeneity differences ͑lung/normal tissue interface, external surface of the patient͒. Based on our algorithm ͑in which the convolution is performed over Ϯ3), the average dose distribution calculated via Eq. ͑1͒ is not accurate in regions within 3 distance of such an interface, and care must be taken in evaluating the dose to volumes in those regions. In regions where Eq. ͑1͒ can be applied, calculation of D (x,y,z) and D (x,y,z)/ͱM can be used to evaluate the stability of a treatment plan. For example, beam angles that may lead to unacceptable variations in dose to normal tissues can be adjusted as necessary. Further, setup situations that may require additional efforts ͑such as daily portal imaging͒ to minimize setup uncertainties can be identified.
Finally, for a single patient geometry, alternative treatment plans can be evaluated in terms of the effects uncertainties have on the plan. As an example, a second treatment plan was designed for the same patient geometry as Fig. 2 . The PTV for the second treatment plan was covered by the 95% isodose surface using three oblique beams. Treatment delivery was planned using the same fractionation scheme ͑58 fractions at 1.5 gray/fraction͒ as plan 1 ͑Fig. 2͒. The distribution of D (x,y,z)/ͱM was calculated for plan 2 and compared to plan 1 as shown in Fig. 8 . The range of possible outcomes about the average expected dose distribution is smaller for treatment plan 1 than for treatment plan 2. Hence, all other factors being equal, we would prefer treatment plan 1, as we are better able to predict the dose to the patient for plan 1 compared with plan 2.
